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Abstract 
The use of monoclonal antibodies directed against membrane proteins of leukocytes has greatly 
contributed to our understanding of the function and development of the immune system. Meanwhile 
these reagents provide valuable tools in many fields of research, stretching far beyond immunology 
and hematology. For guinea pigs only a limited number of such reagents have been described, and 
the information about availability and specificity is scattered over many years and journals. We provide 
an overview on the monoclonal antibodies produced since the technique was applied first in this 
species, with a focus on those reagents which have been characterized in more detail, and which 
should still be available either commercially or directly from the labs that created them. 
 
1. Introduction 
The term “guinea pig” is used in the English language to both refer to the animal species with the Latin 
name Cavia porcellus, and to indicate that a certain animal or human is used as a test subject for 
medical treatments or other kinds of experimental procedures. Although the species stems from the 
South America and has been brought to the old world first in the 16th century, it has coined our 
understanding of an experimental animal in a way that we use the term “experimental animal” and 
“guinea pig” as synonyms. Historically the guinea pig was the most widely used animal model for 
infections in the 18th, 19th and early 20th century, and it largely contributed to the development of the 
concept of infectious diseases caused by pathogenic microorganisms. Although Robert Koch had first 
infected mice with tubercle bacilli, he used guinea pigs to establish bacteria as the etiologic agent that 
causes tuberculosis [1]. The remarkable similarities between humans and guinea pigs in many 
physiological traits have been outlined by several authors [2] and [3], and continue to give reason to 
use guinea pigs as the preferred model for various diseases and pathological conditions affecting 
humans, even if mouse or rat models for the same subject of research exist. 
Regarding the range of available strains, including mutants, transgenic breeds generated by 
homologous recombination, and the availability of research tools such as recombinant cytokines, 
assay systems, and monoclonal antibodies (mAb) to detect and characterize cell lineages based the 
expression of surface antigens, the mouse is largely superior to every other experimental animal. 
Considering susceptibility to certain diseases, disease progression, and the immune response in 
infected mice however, alternative models using guinea pigs, rabbits, rats, and even non-mammalian 
species may turn out more suitable than mice to study a certain condition [4]. Most of these alternative 
models however suffer from a lack of genetically defined strains and absence of the research tools 
listed above. Therefore the mouse is still the most widely used animal for medical research, although 
for many diseases it is certainly not the best. 
There is an abundance of reviews emphasizing the versatility of guinea pigs as research models in 
general [5], [6], [7], [8], [9], [10], [11], [12] and [13] or with reference to infectious diseases and 
vaccination [14], [15], [16], [17], [18], [19], [20], [21] and [22], with a strong focus on tuberculosis 
research [4], [23], [24], [25], [26], [27], [28], [29], [30], [31], [32], [33] and [34]. Guinea pigs represent 
the “gold standard” among small animal models to test the efficiency of new and established vaccines 
against tuberculosis [35], [36] and [37], and are useful for vaccination studies against other diseases 
[38], [39] and [40], but most authors agree that the limited availability of immunological reagents in this 
species strongly restricts its usefulness for modern experimental approaches. As a consequence 
many studies on the immune response to these diseases have been conducted in animal models that 
have less similarity to humans, but have more immunologic reagents available. Although many 
research directions could benefit from an improved availability of monoclonal antibodies in the guinea 
pig, the highest demand is certainly in the area of immunology, vaccination and infectious diseases. 
Several obstacles have affected the development of research reagents for guinea pigs. Most of them 
are associated with the higher costs of purchase and care of guinea pigs as compared to mice and 
rats. At the same time the limited number of inbred strains and the absence of transgenic and 
knockout animals have made guinea pigs less attractive to researchers even if the guinea pig was the 
more appropriate disease model. 
This review aims to summarize efforts undertaken to generate mAb directed against guinea pig 
differentiation antigens. Most guinea pig research reagents were generated with the intention to 
address a specific problem and used solely for that purpose, few studies had the concept to generally 
improve the availability of experimental tools for research in guinea pig models. Therefore the 
available information is scattered over many diverse fields of research and published in various 
journals that are frequently of limited importance for colleagues working in different subjects such as 
veterinary animal science and animal models for human placentation or arthritis. Furthermore, 
frequent requests to our lab for mAb or recombinant proteins developed by others, indicate that the 
demand is high but the information on the source and availability of these reagents is limited, although 
most of the published work is accessible via the internet. 
 
2. Phenotyping of leukocyte populations using differentiation antigens 
expressed on the cell surface 
2.1. Cluster of differentiation antigens 
Although mAb were used to define guinea pig differentiation antigens soon after utilization of the 
technology in human and mouse systems, it was restricted to a few specialized labs [41], [42], [43], 
[44], [45] and [46] and the guinea pig field remained rather neglected when the first workshops to 
define clusters of differentiation (CD) in the human system were held and the nomenclature became 
rapidly adopted to the mouse and rat systems. Meanwhile a number of mAb to guinea pig lymphoid 
and myeloid differentiation antigens have been reported, but only few of them have been assigned to 
the CD nomenclature and even less have been confirmed by molecular biology methods. 
Some of the target antigens have meanwhile been cloned and the specificity of the mAb has been 
confirmed by recombinant expression (see Table 1 remarks). Ideally the identity of the antigen 
recognized by each mAb should be confirmed by cloning of the coding gene and recombinant 
expression into host cells which are otherwise not stained by antibodies directed against the 
respective antigen. Alternatively identification and thorough characterization of the bound protein can 
be performed. Some specificities have been assigned on the basis of potential inter species cross-
reactivity. The anti-CD18 mAb for example were raised in mice against human CD18 and were found 
to cross-react with guinea pig cells. Since the target antigen in guinea pigs has not been identified by 
molecular methods, the specificity of the antibodies is not formally proven. 
 
2.2. MAb directed against cell surface antigens without cluster of differentiation classification 
Many attempts to generate mAb to surface antigens of guinea pig T cells were carried out in order to 
have a marker for the cell population under study or to analyze the consequences of antibody-binding 
for cellular functions. Not much attention was paid to the molecular nature of the recognized antigen or 
its orthologues in other species. Therefore many of these otherwise useful mAb cannot be classified 
following the cluster of differentiation nomenclature. These antibodies are listed in Table 2. 
 
2.3. MAb interfering with cellular effector functions 
Many of the mAb listed in Table 1 and Table 2 interfere with cellular effector functions by blocking 
binding to a physiological ligand or by mimicking interaction with this ligand. Therefore some of these 
antibodies are able to either block the physiological function of the target cell, whereas others show an 
activating effect. Antibodies directed against proteins encoded in the Major Histocompatibility Complex 
(MHC) have been shown to be important for the analysis of MHC restricted antigen presentation. As 
expected, most anti-MHC class I and anti-MHC class II antibodies interfere with the function of class I 
or class II restricted T lymphocytes [42], [47] and [48], i.e. inhibit the response to antigen presented on 
MHC molecules. Similarly, mAb to cytokine receptors inhibit the proliferation of activated T cells 
[44] and [49]. Binding of mAb 188 [50]and H160 [51] to membrane proteins of unknown function 
strongly inhibited antigen- and mitogen-induced T cell proliferation. Cross-linking of GPI-anchored 
surface proteins such as Thy1 by mAb had a strong costimulatory effect on T cell proliferation [52]. 
 
2.4. MAb directed against antigens of the major histocompatibility complex 
Several independent reports have described the production and utilization of anti-MHC antibodies (see 
Table 3 for references). Anti-class II mAb have been classified based on the expression and molecular 
characteristics of the recognized MHC protein, and on their capacity to interfere with class II restricted 
T cell responses [41] and [42]. The specificity of mAb B640 and MSgp 4 for MHC class I has been 
confirmed by cloning and expression of a guinea pig class I gene (unpublished). MAb potentially 
reactive with MHC antigens have been described based on immunohistological staining experiments 
[53], but the specificity has not been confirmed by additional methods. 
 
2.5. Cell surface markers for leukocyte subpopulations 
Although most of the mAb listed so far react with protein antigens on the surface of lymphocytes and 
macrophages, only some of them are appropriate to define populations and subpopulations within 
guinea leukocytes. Many membrane proteins are expressed on a variety of differentiation lineages and 
over long periods of cellular ontogeny. Strictly, only proteins which have a specific task at a specific 
state of cellular development should be expressed selectively on a group of cells with a defined 
function. In reverse, this means that each of these “markers” plays a role in the effector function of the 
cell or serves as receptor for growth factors or for signal transduction. The physiological ligands of 
these receptors might be a soluble mediator such as IL2 or a surface protein of an interacting cell such 
as MHC class I for the CD8 differentiation antigen. 
 
2.5.1. Pan–leukocyte markers 
Due to expression on all nucleated cells, anti-MHC class I mAb may be used to discriminate 
leukocytes from erythrocytes and thrombocytes in the blood and in cell suspensions from 
immunological organs. These antibodies however cannot be used to identify leukocytes on samples 
which contain other nucleated cells such as tissue sections or tumor cells. For the purpose of 
selectively staining leukocytes mAb H201 (anti-Leukocyte Common Antigen, CD45) can be used [54], 
because it provides strong staining of all leukocyte populations and low background on non-leukocytic 
cells. Anti-CD45 mAb specifically recognizing individual isoforms of the leukocyte common antigen 
have been described, which might turn out helpful for the discrimination between native and memory T 
cells subsets (Table 1). 
 
2.5.2. Lymphocyte markers 
In analogy to the rat system and in contrast to mice, Thy-1 (CD90) is expressed on T-and B-cells in 
guinea pigs, although staining of T-lymphocytes using mAb H154 is somewhat stronger than that of B 
cells, and germinal center B cells are completely negative [52]. Therefore antibodies against Thy-1 are 
not T cell markers in this species. Moreover fibroblasts, Langerhans cells and activated macrophages 
stain positive for Thy-1, very weak staining is observed on guinea pig erythrocytes. As in most other 
species, guinea pig Thy-1 is strongly expressed in the brain. In whole blood samples and single cells 
suspensions of spleen and lymph nodes anti-Thy-1 mAb might be useful to discriminate strong 
staining lymphocytes (B- and T cells) from weak or non-stained macrophages and granulocytes. Both 
in tissue sections and in single cell suspensions anti-Thy-1 mAb are helpful to dissect fibroblasts from 
epithelial or endothelial cells [52]. Based on the expression of Thy-1 we consider the guinea pig cell 
line 104C1 [55] as a fibroblast line whereas JH4 clone 1, which has a similar morphology is rather of 
epithelial or endothelial origin (Thy-1 negative). The L2C B cell leukemia line is negative for Thy-1, 
thus resembling germinal center B cells of the lymph node (Table 4). 
2.5.3. T cells 
Only very few mAb can be used as pan T-cell markers in the guinea pig, when compared to human or 
mouse cells. As outlined above Thy-1 is not restricted to T cells in the guinea pig and the expression 
of CD2 which is sometimes used as a T cell marker on human cells has not been identified in guinea 
pigs. Preliminary data from our lab have shown that rabbit antisera raised against recombinant CD3ɛ 
can be used to selectively stain T cells, but so far we have not been able to obtain a monoclonal anti-
CD3 from immunized mice. MAb PC3/188 was raised against a conserved peptide of the CD3ɛ chain 
[56], which is also present on guinea pig T cells, but due to the cytoplasmic location of the epitope, the 
antibody only works with intracellular staining after permeabilization of the cell membrane. Therefore 
the best marker for T-lymphocyte in our hands has been mAb H159 [57]. Although there is weak 
staining of B cells, both populations can be fully separated using H159 both on tissue sections and by 
flow cytometry, the recognized antigen however has not been elucidated, although molecular data on 
the protein have been obtained. Based on these data we proposed H159 to be specific for the T cell 
receptor, but subsequent analysis of TCR proteins and comparison to the antigen detected by H159 
argue against this hypothesis. Activated T lymphocytes and, to a minor extend, resting T cells and 
thymocytes, express Ia antigens in the guinea pig [58]. 
 
2.5.4. T cell subpopulations 
The CD4- and CD8-positive subpopulations can be identified with several independently obtained 
mAb. The CD4-antigen is recognized by mAb H155 [59] and CT7, although the latter has initially been 
described as a pan-T cell marker [60] and cross-blocking studies with H155 have not been carried out 
so far. 
The antibodies B607, CT6, and MSgp6 [47] and [60] all react with the alfa-chain of guinea pig CD8, 
which has meanwhile been confirmed by cloning of guinea pig CD8-alfa and transfection into mouse 
cells (unpublished). CT6 and B607 are of the same isotype (mouse IgG1) and stain quite strongly, 
whereas MSgp6 [61] is a mouse IgM antibody and shows weaker staining. 
Examples for the use of anti-CD4 and anti-CD8 antibodies have been shown exemplarily [47]. In 
double staining experiments individual subpopulations of CD4 and CD8 single positive or double 
positive cells can be distinguished. The same mAb can be used to differentiate responding cells after 
CFSE-labeling and proliferation. Most of these antibodies have been used successfully to identify the 
recognized T cell subsets in cryosections [59], [60] and [61]. 
 
2.5.5. B cells 
Surface IgM bearing B-lymphocytes can be reliably discriminated from other leukocyte populations by 
mAb 31D2 and B621, both directed against guinea pig IgM. After mice and rats were immunized with 
lymph node cells, B cell specific mAb were identified by immunohistochemistry and flow cytometry. 
Further analysis of the recognized antigen showed that 31D2 reacts both with soluble IgM and with 
surface IgM on B lymphocytes. This antibody may be used to deplete B cells from lymph node cells in 
vitro [62]. The specificity of B621 was deduced by partial cross-blocking with 31D2 and by the fact that 
pre-incubation with whole blood (containing soluble IgM) abolishes reactivity with lymphocytes. Most B 




Macrophages are represented by a variety of different cells types in many different organs. Most of 
these differentiation lineages have their own morphology and may possess quite different sets of 
surface antigens. In general most macrophages will express MHC class I antigens (strong staining) 
and class II antigens (variable), the leukocyte common antigen (strong), Thy1 (variable depending on 
activation state) and the antigen recognized by mAb H160 (unpublished). These surface antigens are 
shared with many other cells and can therefore not be considered as macrophage markers. Several 
authors have reported the generation of mAb specific for guinea pig macrophages with a broader or 
narrower expression profile on different macrophage lineages. MAb 342 [63] and MR-1 [64] provide 
specific and sensitive staining of a broad range of macrophages. Due to the intracellular expression of 
the recognized antigen, MR-1 is better suited for immunohistochemistry experiments, whereas mAb 
342 can be used for flowcytometry as well. 
 
2.6. Cross-reactive mAb 
A number of reports have been published on cross-reactive mAb which have been submitted to cluster 
of differentiation workshops for human cells and were simultaneously tested for reactivity with other 
species [65], [66] and [67]. Although this is potentially a fast and straightforward way to obtain useful 
mAb directed against guinea pig differentiation antigens, it has to be kept in mind that a positive 
reaction of a certain antibody with a guinea pig cell population does by no means guarantee that the 
homologous antigen is actually detected. A detailed characterization of the recognized antigen is 
urgently recommended. In the latest report 15 mAb out of 367 raised against human CD antigens 
showed clear cross-reactivity. Five of those however showed staining patterns in guinea pigs which 
were inconsistent with those reported in humans, and for some other antibodies no appropriate guinea 
pig target cells were available for further testing. For eight CD specificities it was concluded that, 
based on the staining pattern, the respective orthologue in the guinea pig was detected, a detailed 
analysis of the recognize antigen however has not been published so far. In a more successful 
approach three out of three mAb directed against human Ia antigens were found to react with Ia 
epitopes of strain 2 guinea pig cells [45]. Similarly, by checking available human anti-CD1 mAb several 
clones were found to cross-react with guinea pig CD1 antigens [68]. Rational design of the immunizing 
peptide based on sequence homology of CD-antigens between different species yielded mAb reacting 
with the target antigen of several animal species including guinea pigs [56]. 
 
3. Cell-lines and T cell hybrids 
In the guinea pig system only a few cell lines showing autonomous growth in tissue culture or as 
transplantable tumors are available. Tissue culture for a variety of primary cells usually can be carried 
out following the protocols developed in other species. 
 
3.1. Guinea pig tumor cell lines 
Unfortunately no lymphocytic or myeloid cell line that can be grown in culture has been obtained from 
guinea pigs so far, restricting the options to immunize and screen with a highly homologous cell 
population for the generation of mAb. The available cell lines were mostly induced by treatment with 
chemical carcinogens and show a rather limited expression of cell surface antigens that can be 
detected with the available mAb. The fibroblast line 104C1 expresses MHC class I and Thy-1 
antigens. The B cell leukemia ENL2C is positive for surface IgM, and class I and class II MHC. The 
variant BZL2C is an Ia negative subclone of the parental L2C cells [69]. 
 
3.2. T cell lines and clones 
Alloreactive and antigen-specific T cell lines can be obtained be repeated restimulation of primed T 
lymphocytes in the presence of guinea pig IL2 or IL15. Expansion and cloning of these cells is 
achieved by following standard protocols [70], [71], [72] and [47]. Cells grown by repeated 
restimulation maintain cellular effector functions in vitro. To obtain highly pure populations of T cells in 
vitro, stimulated T lymphocytes can be grown in medium containing IL2 or IL15 without adding 
macrophages for antigen presentation. Some of these cultures have been grown for several months in 
our laboratory and continue to express T cell markers such as CD3 and the coreceptors CD4 or CD8 
(unpublished observation). 
 
3.3. T cell hybrids 
We have shown, that guinea pig T cells can be fused with mouse and rat thymoma cell lines to 
produce T cell hybrids stably expressing guinea pig cell surface antigens [73]. Although these hybrids 
might be helpful to further characterize the binding specificity of mAb, they appear useless for 
functional studies, because none of these hybrids responded to polyclonal stimulation with the release 
of interleukin 2 (unpublished). 
4. Outlook 
Although the use of guinea pigs as experimental models apparently declines, there is still an 
increasing demand for research reagents in this species. The reasons for the lack of such tools have 
been discussed above, and the drawbacks of the guinea pig system in general, such as high cost, 
long gestation period, few inbred strains and no transgenic animals, are not likely to be resolved in the 
near future, which will in turn prevent many researchers form establishing guinea pig models in their 
lab. Therefore the community of “guinea pig researchers” will remain rather small compared to 
research groups employing mouse models. As a consequence it is rather unlikely that commercial 
suppliers will broaden their range of products in this category, so most of new reagents will have to be 
developed in scientific labs. Raising monoclonal and polyclonal antibodies to guinea pig proteins has 
become much easier with the sequencing of the guinea pig genome. We have used the information 
from public genome libraries to confirm the specificity of mAb against class I molecules and for 
recombinant expression of guinea pig cytokines and differentiation antigens (manuscript in 
preparation). These recombinant proteins have been used successfully to generate monoclonal and 
polyclonal antibodies, which represents a considerable improvement over the use of crude antigens 
such as whole cells or cellular supernatants as immunizing agents. Since guinea pigs, mice and rats 
are quite closely related on the phylogenetic tree, it is sometimes not possible to generate antibodies 
to certain guinea pig proteins in mice or rats. This obstacle has been overcome in the mouse system 
by using hamsters as hosts for the induction of an immune response [74]. We have found, that rabbits 
respond much better to certain recombinant guinea pig antigens than mice or rats (manuscript in 
preparation), and that rabbit polyclonal antibodies raised against guinea pig T cell differentiation 
antigens expressed in Escherichia coli can be used to specifically detect the protein on the cell surface 
by flow cytometry. With the recently described parental cell line developed in transgenic rabbits [75] it 
should be possible to produce mAb with the same specificity. The technique however is currently 
limited to commercial suppliers, because the parental line has not been made available to research 
laboratories. 
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CD1 Most CD1 isoforms 
CD1F2/5E3 
Mouse IgG1 
Specificity verified on 
transfected cell lines 
[68] 
CD1 All CD1 isoforms 
CD1F2/6B5 
Mouse IgG1 
Specificity verified on 
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Specificity verified on 
transfected cell lines 
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CD5 CD5 8BE6 
 
[77], 
[78] and [79] 




Binds to CD8a chain, 
gene cloned, specificity 
verified on transfected 
cell lines 
[47] 




Binds to CD8a chain, 
gene cloned, specificity 
verified on transfected 
cell lines 
[60] 




Binds to CD8a chain, 
gene cloned [80], 
specificity verified on 
transfected cell lines 





LFA-1, Mac-1, etc. 
IB4 
Mouse 
Raised against human 







LFA-1, Mac-1, etc. 
R15.7 
Mouse 
Raised against human 















antigen (LCA) all 
IH-1 
Mouse 



























Reacts with most 
leucocytes, but only 










regulatory activity on 
guinea pig erythrocytes 
[84] and [85] 
















Similar to H154, but 
mouse mAb, gene 
cloned 
[52], 
[60] and [87] 
CD90 Thy-1 antigen 
MSgp2 
Mouse 
Similar to H154 and 
CT4 but weaker staining 
[52] and [88] 
CD90 Thy-1 antigen 
167 
Mouse 

























T cells Weak staining of B cells [57] 
5C3 ms IgM Activated T cells Blocks IL2-driven proliferation [44] and [49] 
CT5 ms IgG1 
T cells and leukemic 
B cells 
Considered as pan T cell 
marker, but also stains L2C B 
cell leukemia 
[60] 
MSgp7 ms IgM T cells 
Reacts with T cells and 
thymocytes 
[48] 
MSgp12 ms IgG1 T cells 
Reacts with a subpopulation of 
T cells and thymocytes 
potential anti-CD4 
[48] 
31D2 ms IgG1 B cells (surface IgM) 
Binds soluble and surface IgM, 














T- and B-cells 
Inhibits T cell proliferation, 








Strongly inhibits T cell 
proliferation  
342 ms IgM Macrophages Broad range of macrophages [63] 
   
Good induction of complement-




Macrophages Stains most macrophages [63] 




MR-1 ms IgG1 
Macrophages and 
monocytes 
Intracellular antigen [64] 
VIIA1 ms IgG1 Macrophages binds Fc Receptor 2 [89] 











Table 3. MHC-specific monoclonal antibodies. 
Antibody-
name 






Stains all immune cells except cortical 
thymocytes, immunoprecipitated a 45 kD 
antigen and beta-2-microglobulin 






Similar to MSgp4, specificity confirmed by 























Inhibits T cell-proliferation 
Strain 2 specific 
[41], 






Inhibits T cell-proliferation 
Reacts with cells of strain 2 and strain 13 
animals 
[41], 





Specific for strain 13 and outbred gpips, 














Table 4. Guinea pig tumor cell lines. 




104 C1 Fibroblast LUNG Adherent CRL-1405 [55] 
JH4 clone 1 Fibroblast/epithelial FETUS Adherent CCL-158 [90] 
GPC 16 Epithelial Colon Adherent CCL-242 [91] 
EN L2C Lymphoid Blood 
In 
vivo/leukemia 
n.a. [92] and [93] 




Line-10 Variable Liver In vivo/ascites n.a. [95] 
 
